LECANEMAB
BAN2401-G000-303
Phase 3 small_molecule active
Quick answer
LECANEMAB for Early Preclinical Alzheimer’s Disease and Intermediate Amyloid, Preclinical Alzheimer’s Disease and Elevated Amyloid is a Phase 3 program (small_molecule) at Eisai GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eisai GmbH
- Indication
- Early Preclinical Alzheimer’s Disease and Intermediate Amyloid, Preclinical Alzheimer’s Disease and Elevated Amyloid
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active